Evidence map›Paper›PMID 40135930›Full record

ArticleJournal of viral hepatitis2025

Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality.

Annabel A Powell, Annastella Costella, Rachel Roche, David Leeman, Ashley Brown, Beatrice Emmanouil, Mark Gillyon-Powell, Ross Harris, Holly D Mitchell, Ruth Simmons and 1 more

Abstract read
In one paragraph

Article in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annabel A PowellBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
Annastella CostellaBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
Rachel RocheBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
David LeemanBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
Ashley BrownDepartment of Hepatology, Imperial College London, Imperial College NIHR BRC, London, UK.ORCID https://orcid.org/0000-0002-3167-7087
Beatrice EmmanouilHCV Elimination, NHS England, London, UK.
Mark Gillyon-PowellHCV Elimination, NHS England, London, UK.
Ross HarrisBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
Holly D MitchellBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
Ruth SimmonsBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
Monica DesaiBlood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The United Kingdom, along with many other countries, is working towards eliminating viral hepatitis as a public health threat by 2030, with a combined mortality target of less than or equal to six deaths per 100,000 population. The current methodology of reporting uses death registrations alone, which has been estimated to underestimate mortality rates by up to 60% for hepatitis C (HCV)-related liver disease. We aim to conduct a sensitivity analysis using data linkage of death certificates, hepatitis B (HBV) and HCV diagnoses and admissions for end-stage liver disease (ESLD) and/or hepatocellular carcinoma (HCC) to estimate mortality rates, assess progress towards elimination and evaluate underreporting. Between 2000 and 2023, 7967 deaths were reported due to HBV- and/or HCV-associated ESLD and/or HCC. Using data linkage of all three datasets, this increased to 11,487, with underreporting estimated to be 37% overall. The upper bound combined mortality rate was estimated to be 1.3 deaths per 100,000 population at its peak in 2015, therefore surpassing the WHO target for all years evaluated. From 2015 to 2023, both HCV-associated ESLD and/or HCC mortality decreased (1.12 to 0.88 deaths per 100,000 population), however, there was a slight increase for HBV-associated ESLD and/or HCC deaths during the same time frame (0.3 to 0.35). A higher proportion of HBV-related deaths were in males (p < 0.05) who died outside London (p < 0.05) and a lower proportion were White (p < 0.05) when compared to HCV-related deaths. While England has met the WHO impact targets, it is important we continue to drive reductions in mortality.

Indexed as

Hepatitis BHepatitis CInformation Storage and RetrievalAdolescentAdultAgedAged, 80 and overCarcinoma, HepatocellularEnd Stage Liver DiseaseEnglandFemaleHumansLiver NeoplasmsMaleMiddle AgedWorld Health Organizationdata linkagehepatitis Bhepatitis Cmortality

Identifiers

PMID40135930
PMCPMC11938805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.